About Rua Diagnostics
Rua Diagnostics is building a portable device that analyzes compounds in a person's breath. Its machine-learning software looks for signs of diseases such as lung cancer, colorectal cancer and COVID-19. Rua Diagnostics' BreathScan technology is for investigational use only and has not been cleared or approved by the FDA.
Rua is based in Westbury, New York, and licensed its core technology from the University of Michigan in 2023. Jillian Levovitz is CEO and president, and Jonathan Orr chairs the board.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| May 13, 2026 | May 27, 2026 | $3,650,000fully sold | 5 | $730K | EquityRule 506(b) | Form D ↗ |
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed Rua Diagnostics
Investors backed Rua Diagnostics for a breath test that could screen for several diseases from a single sample. Its device shrinks gas chromatography, a laboratory method for separating chemical compounds, into a portable unit, and software reads the results in about 30 minutes. The technology comes from the University of Michigan, and the device is still investigational.
The problem it targets
Breath carries traces of compounds that can signal disease, but measuring them at very low levels has needed large laboratory systems. Rua's device brings parts-per-trillion sensitivity, previously found only in such systems, into a portable unit that does not require specialist training.
What the product does
The device collects one breath sample and separates the compounds in it with photo-ionization and microfluidic technology. Trained algorithms then analyze the data to assess disease and predict outcomes, in 30 minutes or less. Rua names lung cancer, colorectal cancer and COVID-19 among its targets, and a cloud platform is meant to add new tests over time.
Progress so far
Rua licensed breath-analysis technology from the University of Michigan in 2023. The inventors, Xudong (Sherman) Fan and Kevin Ward, work at the university's Weil Institute for Critical Care Research and Innovation. Both hold equity in Rua, Michigan Medicine reported in April 2025, when the company joined the I-CREATE accelerator. In 2023 Optimus Healthcare Services also signed a memorandum of understanding with Rua.
We wrote this summary from public statements by Rua Diagnostics and its investors. It is not investment advice.
Rua Diagnostics in the News
Leadership Team
Executive officers and directors listed on Rua Diagnostics's Form D filed May 27, 2026.
Sources
- SECRua Diagnostics Inc. filing history
- Company siteAbout page on ruadiagnostics.com
- Company siteSolutions page on ruadiagnostics.com
- SEC filingOptimus Healthcare Services S-1/A, July 2024 (gives KORR Acquisitions Group's Westbury address)
- ResearchUniversity of Michigan Weil Institute: breath analysis device, licensed to RUA Diagnostics in 2023
- PressOptimus Healthcare Services release: memorandum of understanding with RUA Diagnostics (2023)
- SECOptimus Healthcare Services 8-K: wind-down, directors and officers resign (July 17, 2026)